California, USA- January 2024- Guardant Health, a prominent precision oncology company, and Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, have joined forces to extend the reach of Guardant Health’s liquid and tissue biopsy tests for cancer screening, recurrence monitoring, and tumor mutation profiling across all solid cancers in countries throughout the Middle East and North Africa (MENA).
However, This collaboration marks an expansion of Guardant Health’s global footprint, encompassing products along the entire cancer care continuum. The suite of tests includes Shield™ for cancer screening and early detection, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers.
Moreover, Guardant Health’s tests, utilized in over 60 countries, will be more accessible in the Middle East and North Africa through a partnership with Hikma. Additionally, The collaboration aims to address the region’s anticipated doubling of cancer cases by 2040.
“Guardant Health is excited to partner with Hikma and leverage their strong commercial capabilities and regional expertise to equip oncologists in MENA with the necessary tools for cancer screening, recurrence monitoring and guiding treatment selection,” said Simranjit Singh, Guardant Health AMEA CEO.
Also Read: Varian and Nova Scotia Health’s Oncology Partnership for Cancer Advancements
“Our partnership with Guardant Health adds next-generation sequencing diagnostics that can potentially transform cancer care in MENA bringing hope to patients facing this challenging journey. We are excited to partner with Guardant Health, as their offering can help patients at all stages of the disease – from screening to monitoring cancer recurrence to guiding treatment decisions. Hikma, as a leading healthcare company in MENA, is committed to advancing precision medicine. Our robust oncology portfolio includes generics, biologics, immunotherapy, and cutting-edge innovations. This commitment aims to achieve improved treatment outcomes for patients with cancer,” said Mazen Darwazah, Hikma’s executive vice chairman and president of MENA.
